Pfizer shared an update last week on its clinical trial for VALOR, which is short for "Vaccine Against Lyme for Outdoor Recreationists." The drugmaker said in its report that the vaccine was ...

Since pharmaceutical companies Pfizer and Valneva announced positive results from their phase 3 trial of a vaccine to prevent Lyme disease last month, two questions have loomed large: Will the vaccine ...

Scientists developing vaccines and anti-tick treatments amid growing concern over spread of disease ...

Pfizer said it will seek regulatory approval for a Lyme disease vaccine candidate despite failing a late-stage trial. Pfizer said not enough people contracted Lyme disease to be confident in the ...

The following companies are leading this vector-borne boon, each tackling the problem from a different technological angle: ...

This week, Pfizer and French vaccine company, Valneva, released phase 3 clinical trial data for PF-0730740, a four-dose Lyme disease vaccine they developed together that is about 70% effective. While ...

Earlier this week, pharmaceutical company Pfizer and its partner Valneva announced that an experimental Lyme disease vaccine showed more than 70% efficacy in late-stage clinical trials. The candidate, ...

Pfizer and Valneva said Monday their Lyme disease vaccine showed more than 70% efficacy in a late-stage study, even as it missed its main goal. Subscribe to read this story ad-free Get unlimited ...

As part of his “Take Back Your Health” tour, RFK Jr. was at the state capital in Concord talking ticks and Lyme disease.